ArticleFrontiers in cell and developmental biology2026
miR-495 suppresses osteosarcoma growth and metastasis by directly targeting RUNX3 in the PI3K/Akt pathway
Article in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to identify miR-495 as a potential regulator in osteosarcoma and characterize its role in tumor progression and underlying signaling pathways. Methods: Differentially expressed miRNAs in osteosarcoma were screened from the GSE39058 dataset using bioinformatics analysis. miR-495 expression was validated in tissues/cells using S-MED database and qPCR. Functional assays, including proliferation, invasion, and apoptosis analyses, were performed following transfection with miR-495 mimics or inhibitors. Transcriptome sequencing combined with dual-luciferase assays identified RUNX3 as a direct target, and Western blot analyzed PI3K/Akt pathway activation. Results: miR-495 was downregulated in osteosarcoma tissues/cells, positively correlating with patient survival. miR-495 overexpression inhibited cell proliferation, invasion, and migration, while promoting apoptosis by suppressing PI3K/Akt pathway (downregulating p-Akt, Bcl-2; upregulating Bax, c-casp3). RUNX3 overexpression rescued these effects, confirming it as a functional target. Conclusion: miR-495 acts as a tumor suppressor in osteosarcoma by targeting RUNX3 to inhibit PI3K/Akt signaling, suggesting its potential as a prognostic marker and therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.